Altuvoct: Innovative Medicinal Products Benefit from Innovative Approaches to Regulatory Assessment

Area of Science:

• Biochemistry
• Hematology
• Pharmacology

Background:

• Severe haemophilia A is a serious bleeding disorder.
• Current treatments have limitations.
• Efanesoctocog alfa offers a new therapeutic option.

Purpose of the Study:

• To evaluate the efficacy and safety of efanesoctocog alfa (Altuvoct) in patients with severe haemophilia A.
• To assess the pharmacokinetic profile and clinical benefit of Altuvoct.

Main Methods:

• Two single-arm ongoing studies (XTEND-1 and XTEND-kids) enrolled 233 patients with severe haemophilia A.
• Pharmacokinetic analysis and causal inference modeling were employed.
• Benefit-risk evaluation was conducted.

Main Results:

• Efanesoctocog alfa demonstrated a plasma half-life of approximately 40 hours.
• The treatment showed a positive benefit-risk evaluation in the target population.
• The claim for Altuvoct's indication in severe (and moderate) haemophilia A was supported.

Conclusions:

• Efanesoctocog alfa (Altuvoct) is a promising treatment for severe haemophilia A.
• The drug is indicated for patients aged two years and older.
• The positive benefit-risk assessment supports its use in clinical practice.